✦ LIBER ✦

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

✍ Scribed by Breton, Caroline S; Nahimana, Aimable; Aubry, Dominique; Macoin, Julie; Moretti, Pierre; Bertschinger, Martin; Hou, Samuel; Duchosal, Michel A; Back, Jonathan

Book ID: 125403609
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 843 KB
Volume: 7
Category: Article
ISSN: 1756-8722
DOI: 10.1186/1756-8722-7-33

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A novel Fc-engineered monoclonal antibod

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies

✍ Heider, K.-H.; Kiefer, K.; Zenz, T.; Volden, M.; Stilgenbauer, S.; Ostermann, E. 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 604 KB

Chimeric, divalent and tetravalent anti-

Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines

✍ Xiao-Yun Liu; Laurentiu M. Pop; Lydia Tsai; Iliodora V. Pop; Ellen S. Vitetta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 295 KB

## Abstract CD19 is an attractive therapeutic target for treating human B‐cell tumors. In our study, chimeric (c) divalent (cHD37) and tetravalent (cHD37‐DcVV) anti‐CD19 monoclonal antibodies (MAbs) were constructed, expressed and evaluated for their binding to human 19‐positive (CD19^+^) tumor cel